Related Experiment Videos
Does proctosigmoiditis in inflammatory bowel disease presage the imminent onset of symptoms?
1Department of Pediatrics and Laboratories, North Shore University Hospital, Manhasset, NY 11030.
Insights
Asymptomatic children and adolescents with inflammatory bowel disease (IBD) and anorectosigmoid inflammation can remain symptom-free without intrarectal therapy. Active inflammation does not always predict symptoms, guiding treatment decisions.
Area of Science:
- Pediatric Gastroenterology
- Inflammatory Bowel Disease Research
- Clinical Trial Analysis
Background:
- Children and adolescents with inflammatory bowel disease (IBD) often present with anorectal inflammation.
- The necessity of intrarectal therapy based solely on endoscopic and histological evidence of anorectosigmoid inflammation in asymptomatic pediatric IBD patients is unclear.
Purpose of the Study:
- To evaluate if asymptomatic pediatric patients with moderate to severe anorectosigmoid inflammation remain symptom-free for 12 months without intrarectal therapy.
- To determine the correlation between anorectosigmoid inflammation and symptom development in pediatric IBD.
- To inform clinical decision-making regarding the initiation of intrarectal therapy.
Main Methods:
- Prospective study of 13 asymptomatic pediatric patients (ages 6-21) with IBD and anorectosigmoid inflammation.
- Four patients with moderate to severe inflammation underwent a 12-month follow-up without intrarectal treatment.
- Patients were on existing systemic therapies (sulfasalazine, methylprednisolone, 6-mercaptopurine).
Main Results:
- All four patients with moderate to severe anorectosigmoid inflammation remained asymptomatic for 12 months.
- The presence of endoscopic and histological inflammation did not correlate with symptom onset.
- Systemic therapy alone was sufficient to maintain asymptomatic status in this cohort.
Conclusions:
- Anorectosigmoid inflammation in asymptomatic pediatric IBD patients does not necessitate intrarectal therapy.
- Clinical symptoms, rather than endoscopic or histological findings alone, should guide treatment decisions for proctosigmoiditis in pediatric IBD.
- This study suggests a potential de-escalation of intrarectal treatment based on patient symptomatology.
Abstract:
This study was undertaken to determine if asymptomatic children and adolescents with inflammatory bowel disease and moderate to severe anorectosigmoid inflammation might remain symptom-free for at least 12 months without specific intrarectal therapy. We prospectively studied 13 asymptomatic patients 6-21 years of age (four with Crohn's disease and nine with nonspecific colitis) with previously documented anorectosigmoid inflammation. Of these 13, four had moderate to severe anorectosigmoid inflammation both endoscopically and histologically. These four patients (two with Crohn's disease and two with nonspecific colitis) were entered into the second phase of the study. Three were receiving sulfasalazine, and one received methylprednisolone, 4 mg/day, and 6-mercaptopurine, 50 mg/day. None received intrarectal therapy. Clinical evaluation revealed that all four remained asymptomatic for 12 months despite the continued presence of moderate to severe anorectosigmoid inflammation. These results indicate that in children and adolescents with inflammatory bowel disease, the presence of inflammation of the anorectosigmoid does not necessarily correlate with or presage the onset of symptoms of proctosigmoiditis. Therefore, active inflammation of the anorectosigmoid is not the sole prerequisite for intrarectal therapy. The clinician should be guided by the symptoms of the patient, not by the presence or absence of active anorectosigmoid inflammation.